Q-omics provides the consensus-scored CLDN20 profile across patient tissues and cancer cell-line models. CLDN20 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, CLDN20 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CLDN20 RNA expression shows 20,295 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, KIRC, and THYM as cancer lineages where CLDN20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN20 survival associations across molecular data types. CLDN20 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN20 RNA expression–survival associations across cancer types. High CLDN20 expression shows unfavorable associations in LGG and OV, but favorable associations in READ, UCS, LUSC and SCLC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for CLDN20 RNA expression.
This table summarizes CLDN20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLDN20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN20 shows lower tumor expression in KIRC, KIRP, THCA and KICH and higher tumor expression in COAD and LUSC. The KIRC box plot shows higher CLDN20 RNA expression in normal versus tumor tissue (log2 FC = −0.318, t-test p < 0.001).
This table shows molecular features associated with CLDN20 in patient tissues and cancer cell lines. In patient samples, CLDN20 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
